Vanda Pharmaceuticals
Stock Forecast, Prediction & Price Target
Vanda Pharmaceuticals Financial Estimates
Vanda Pharmaceuticals Revenue Estimates
Vanda Pharmaceuticals EBITDA Estimates
Vanda Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $268.68M N/A | $254.38M -5.32% | $192.64M -24.27% | Avg: $175.3M Low: $175.3M High: $175.3M avg. -9.00% | Avg: $152.1M Low: $152.1M High: $152.1M avg. -13.23% | ||
Net Income
% change YoY
| $33.15M N/A | $6.27M -81.07% | $2.50M -60.01% | Avg: $-28.1M Low: $-27.62M High: $-27.62M avg. -1219.96% | Avg: $7.48M Low: $7.48M High: $7.48M avg. 126.62% | ||
EBITDA
% change YoY
| $43.64M N/A | $7.84M -82.02% | $-10.94M -239.47% | Avg: $12.78M Low: $12.78M High: $12.78M avg. 216.88% | Avg: $11.09M Low: $11.09M High: $11.09M avg. -13.23% | ||
EPS
% change YoY
| $0.6 N/A | $0.11 -81.66% | $0.04 -60.27% | Avg: -$0.48 Low: -$0.48 High: -$0.48 avg. -1198.39% | Avg: $0.13 Low: $0.13 High: $0.13 avg. 127.08% | ||
Operating Expenses
% change YoY
| $200.88M N/A | $223.77M 11.39% | $191.79M -14.28% | Avg: $95.41M Low: $95.41M High: $95.41M avg. -50.25% | Avg: $82.78M Low: $82.78M High: $82.78M avg. -13.23% | ||
FAQ
What is Vanda Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -546.66% in 2025-2026.
We have gathered data from 1 analysts. Their low estimate is -27.62M, average is -28.1M and high is -27.62M.
What is Vanda Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of -11.11% in 2025-2026.
We have gathered data from 1 analysts. Their low revenue estimate is $175.3M, average is $175.3M and high is $175.3M.
What is Vanda Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -535.65% in 2025-2026.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$0.48, average is -$0.48 and high is $-0.48.
What is the best performing analyst?
In the last twelve months analysts have been covering Vanda Pharmaceuticals stock. The most successful analyst is Charles Duncan.